Skip to main
SPRY

SPRY Stock Forecast & Price Target

SPRY Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ARS Pharmaceuticals is a biopharmaceutical company with a strong focus on the development and commercialization of their intranasal epinephrine product, neffy. Their strategic plan, partnerships and encouraging clinical data in chronic spontaneous urticaria (CSU) position neffy as a strong contender in the market, and we believe it has the potential to capture a significant share of the growing epinephrine market. While the lack of new commercial formulary additions or coverage decisions in July 2026 may have been viewed negatively by investors, we believe the value of neffy remains largely intact and the upcoming data for ARS-2 in CSU offers further potential upside for the company.

Bears say

ARS Pharmaceuticals is facing challenges with its neffy commercial rollout due to increasing competition and pressure in the PBM market, as well as CEO and other management changes. The company's pharmacy reimbursement model is attempting to stabilize its reimbursement rates, but may require time to be successful. Additionally, while ARS-2 remains a potential game-changer in the CSU market, there are newer therapies in development that could decrease the frequency of flares and limit the need for ARS-2, and the company may face challenges with cost-sharing for patients. These factors contribute to a negative outlook for the stock.

SPRY has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ARS Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ARS Pharmaceuticals Inc (SPRY) Forecast

Analysts have given SPRY a Buy based on their latest research and market trends.

According to 3 analysts, SPRY has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ARS Pharmaceuticals Inc (SPRY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.